What is Palvella Therapeutics's preferred stock?

Palvella Therapeutics (PVLA) reported preferred stock of $0 in Q4 2025.

What does preferred stock mean?

Equity securities with priority over common stock for dividends and liquidation proceeds, but typically without voting rights.

Palvella Therapeutics PVLA Preferred Stock

Preferred Stock at other companies

Relay Therapeutics, Inc.RLAY

$0—

ANI PharmaceuticalsANIP

$0—

Kodiak Sciences IncKOD

$0—

Ultragenyx PharmaceuticalRARE

$0—

LQD

Liquidia CorporationLQDA

$0—

Ligand PharmaceuticalsLGND

$0—

Other financials

Income statement

See full

Revenue$53.0K-97.3%

Operating income-$14.9M-88.7%

Net income-$15.8M-92.6%

EPS (diluted)-$1.20-62.2%

Balance sheet

See full

Cash & equivalents$206.4M+173%

Total debt$584.0K—

Total equity$232.3M+318%

Total assets$263.8M+232%

Cash flow

See full

Operating cash flow-$10.9M-60.5%

CapEx--100%

Free cash flow-$2.7M+72.0%

Valuation

See full

Market cap$1.7B+468%

Enterprise value$1.5B—

P/S41.6×—

Profitability

See full

Operating margin-183.2%-13.5pp

Net margin71.7%+40.4pp

FCF margin-99.8%-34.2pp

Returns & leverage

See full

Return on equity-34.2%—

Debt / equity0×—

Current ratio28.9×+20.0×

Where this comes from

Reported directly by Palvella Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockValue.

The official record: Palvella Therapeutics’s 10-K, filed March 31, 2026, on SEC EDGAR. View the filing →

Ask your AI about Palvella Therapeutics's preferred stock.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Palvella Therapeutics's preferred stock?: Palvella Therapeutics (PVLA) reported preferred stock of $0 in Q4 2025.
What does preferred stock mean?: Equity securities with priority over common stock for dividends and liquidation proceeds, but typically without voting rights.